Systemic Chemotherapy in Brain Gliomas

作者: George A. Alexiou , Athanasios P. Kyritsis

DOI: 10.1007/978-3-319-95918-4_24

关键词:

摘要: Gliomas constitute the most common and difficult to treat primary brain tumors, accounting for over 50% of all central nervous system tumors. The glioblastoma is by far frequently occurring malignant glial with a median patient survival 15 months. Current treatment involves maximal surgical resection followed radiotherapy concomitant adjuvant chemotherapy. However, last decade much has changed regarding role chemotherapy in gliomas. This result several trials that reported benefit combination agents incorporation molecular genetic markers as predictors response Herewith we discuss regimens currently used glioma well associated toxicities try provide an insight into future advancements.

参考文章(50)
Edwards Ms, Seager Ml, Townsend Jj, Schimberg Tp, Wright Dc, Wilson Cb, Levin Va, Modified procarbazine, CCNU, and vincristine (PCV 3) combination chemotherapy in the treatment of malignant brain tumors. Cancer treatment reports. ,vol. 64, pp. 237- 244 ,(1980)
C A Meyers, M A Weitzner, A D Valentine, V A Levin, Methylphenidate therapy improves cognition, mood, and function of brain tumor patients. Journal of Clinical Oncology. ,vol. 16, pp. 2522- 2527 ,(1998) , 10.1200/JCO.1998.16.7.2522
Mustafa Khasraw, David Bell, Helen Wheeler, Long-term use of temozolomide: Could you use temozolomide safely for life in gliomas? Journal of Clinical Neuroscience. ,vol. 16, pp. 854- 855 ,(2009) , 10.1016/J.JOCN.2008.09.005
George A. Alexiou, Konstantinos I. Tsamis, Athanasios P. Kyritsis, Targeting Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand (TRAIL): A Promising Therapeutic Strategy in Gliomas Seminars in Pediatric Neurology. ,vol. 22, pp. 35- 39 ,(2015) , 10.1016/J.SPEN.2014.12.002
Jon Glass, Fred H. Hochberg, Michael L. Gruber, David N. Louis, David Smith, Barbara Rattner, The treatment of oligodendrogliomas and mixed oligodendroglioma-astrocytomas with PCV chemotherapy Journal of Neurosurgery. ,vol. 76, pp. 741- 745 ,(1992) , 10.3171/JNS.1992.76.5.0741
George A. Alexiou, Anna Goussia, Spyridon Voulgaris, Andreas D. Fotopoulos, George Fotakopoulos, Antigoni Ntoulia, Anastasia Zikou, Perikles Tsekeris, Maria I. Argyropoulou, Athanasios P. Kyritsis, Prognostic significance of MRP5 immunohistochemical expression in glioblastoma Cancer Chemotherapy and Pharmacology. ,vol. 69, pp. 1387- 1391 ,(2012) , 10.1007/S00280-012-1832-Z
George Shenouda, Luis Souhami, Carolyn R. Freeman, Joseph Hazel, Shirley Lehnert, Lawrence Joseph, Accelerated fractionation for high‐grade cerebral astrocytomas. Preliminary treatment results Cancer. ,vol. 67, pp. 2247- 2252 ,(1991) , 10.1002/1097-0142(19910501)67:9<2247::AID-CNCR2820670906>3.0.CO;2-Q
Sanjaykumar Hapani, Amna Sher, David Chu, Shenhong Wu, Increased risk of serious hemorrhage with bevacizumab in cancer patients: a meta-analysis Oncology. ,vol. 79, pp. 27- 38 ,(2010) , 10.1159/000314980
Xiaolei Zhu, Shenhong Wu, William L. Dahut, Chirag R. Parikh, Risks of Proteinuria and Hypertension With Bevacizumab, an Antibody Against Vascular Endothelial Growth Factor: Systematic Review and Meta-Analysis American Journal of Kidney Diseases. ,vol. 49, pp. 186- 193 ,(2007) , 10.1053/J.AJKD.2006.11.039